# DESCRIPTION

## FIELD OF THE INVENTION

- relate to modified recombinant binding proteins

## BACKGROUND OF THE INVENTION

- introduce angiogenesis
- motivate VEGF-A as target
- describe VEGF-A ligands
- describe VEGFR tyrosine kinases
- describe neuropilin as receptor
- describe VEGF-A isoforms
- describe pro-angiogenic VEGF-Axxx
- describe anti-angiogenic VEGF-Axxxb
- describe approaches to inhibiting VEGF-A signaling
- describe VEGF-A targeted therapy
- describe limitations of current therapies
- describe designed repeat domains
- describe WO 02/20565
- motivate need for improved anti-angiogenic agents

## SUMMARY OF THE INVENTION

- describe recombinant binding protein

## DETAILED DESCRIPTION OF THE INVENTION

- define VEGF-Axxx isoforms
- specify binding domain for VEGF-Axxx
- define protein
- explain protein domain
- define recombinant
- describe recombinant DNA technology
- define polypeptide tag
- list examples of polypeptide tags
- define polypeptide linker
- list examples of polypeptide linkers
- define polypeptide
- specify minimum length of polypeptide
- define proteinaceous polymer moiety
- describe properties of proteinaceous polymer moiety
- specify molecular weight of proteinaceous polymer moiety
- define non-proteinaceous polymer moiety
- list examples of non-proteinaceous polymer moieties
- describe PEGylation
- define binding protein
- specify components of binding protein
- describe multimerization moieties
- specify molecular weight of binding protein
- define binding domain
- describe protein scaffold
- specify examples of protein scaffolds
- define predetermined property
- specify screening and selection methods
- exclude antibodies and fragments
- exclude immunoglobulin fold
- exclude immunoglobulin-like domain
- specify anti-angiogenic effects
- describe sprouting assay
- specify length of binding domain
- exclude free Cys residue
- specify repeat domain
- describe designed ankyrin repeat domain
- define repeat proteins
- specify components of repeat proteins
- define designed repeat protein
- describe structural unit
- define structural motif
- define repeat unit
- specify examples of repeat units
- define repeat sequence motif
- describe folding topology
- define capping module
- define target
- define binding domain
- specify Kd for VEGF-Axxx and VEGFR-2 interaction
- describe method to determine dissociation constants
- define preferred binding domain
- define term "PBS"
- specify stability of binding protein/domain in PBS
- describe embodiment of binding protein with midpoint denaturation temperature and non-aggregating properties
- define term "HUVEC"
- describe assay to measure sprouting of HUVEC spheroids
- define IC50 value
- specify preferred IC50 value for binding protein/domain
- describe monomeric binding protein/domain with IC50 value
- specify Kd for interaction of binding domain with VEGF-B, VEGF-C, VEGF-D, PIGF, or PD
- describe recombinant binding protein with repeat domain
- specify conjugation of PEG moiety to binding domain
- describe competition for binding to VEGF-Axxx
- describe recombinant binding protein with repeat domain and PEGylation
- describe pharmaceutical and diagnostic compositions
- define edema
- describe consequences of edema
- define angiogenesis
- describe pathological angiogenesis
- describe retinal ischemic diseases
- describe diabetic retinopathy
- describe macular degeneration
- describe diabetic macular edema
- describe biochemical mechanisms of DR/DME
- describe pulmonary hypertension
- describe inflammation
- describe tumor formation
- describe characteristics of tumors
- describe types of tumors
- describe use of binding proteins against tumors
- describe pharmaceutical composition
- describe carriers, excipients, or stabilizers
- describe combination formulations
- describe preferred pharmaceutical composition for eye diseases
- describe administration methods
- describe sustained-release preparations
- describe intraocular implant
- describe pharmaceutical composition administration
- describe dosage and mode of administration
- describe continuous infusion
- describe administration by eye drops
- describe combination therapy with PIGF inhibitor
- describe combination therapy with other inhibitors
- describe method of treating retinopathy
- describe method of inhibiting VEGF-A biological activity
- describe method of treating a subject with a condition
- describe conditions suitable for treatment
- describe preferred conditions suitable for treatment
- describe obtaining recombinant binding protein
- describe evolving recombinant binding protein
- describe library of ankyrin repeat proteins
- describe selection or screening of VEGF-Axxx specific DARPins
- describe modular assembly of repeat domains
- describe general outline of the invention

## EXAMPLES

- introduce materials
- describe molecular biology methods
- outline designed ankyrin repeat protein libraries
- confirm DNA sequences and molecular weights

### Example 1

- select binding proteins with repeat domain and VEGF-Axxx specificity
- perform ribosome display selection rounds
- identify specific VEGF-Axxx binding clones by ELISA
- express and purify selected clones
- analyze repeat sequence motifs from selected repeat domains
- express and purify DARPins with high level and solubility
- describe crude extract ELISA procedure
- analyze results of crude extract ELISA
- deduce repeat sequence motifs from selected repeat domains
- express and purify DARPins with high level and solubility
- describe purification procedure
- analyze purity of purified DARPins
- use purified DARPins for further characterization

### Example 2

- determine IC50 values of selected DARPins in spheroid outgrowth assay
- describe spheroid outgrowth assay procedure
- analyze results of spheroid outgrowth assay

### Example 3

- determine target specificity of DARPin #27 by SPR analysis
- describe SPR analysis procedure

### Example 4

- determine in vivo efficacy of DARPin #30 in vascular leakage rabbit model
- describe vascular leakage inhibition measurements in rabbits
- prepare PEGylated DARPin #30
- describe PEGylation procedure
- analyze results of vascular leakage inhibition measurements
- measure intravitreal terminal half-lives of binding proteins
- analyze results of intravitreal terminal half-lives measurement

### Example 5

- describe recombinant binding proteins with repeat domain and proteinaceous polymer moiety
- express and purify recombinant binding proteins
- describe expression and purification procedure
- conjugate repeat proteins to non-proteinaceous polymer moiety
- describe conjugation procedure
- purify PEGylated repeat proteins
- analyze results of PEGylation
- describe structure of PEGylated repeat proteins

